International Projects
| Project title: | EMINTECH: Emerging Innovative Technologies against AMR and rare diseases (EMINTECH) |
|---|---|
| Reference Number: | SIPC-20241004 |
| Partners: | Fagoterapia Lab (IT) Biotalentum LTd (HU) Sylentis (ES) Oryzon (ES) Minoryx (ES) |
| Funding Agency: | This project has been funded by CDTI, as a result of Reig Jofre’s participation as an associate member in the first European IPCEI Med4Cure project (Important Project of Common European Interest).
|
| Objetive: | EMINTECH is Reig Jofre’s initiative to tackle two major global health challenges: antimicrobial resistance (AMR) and rare diseases. With an investment of over €25 million, the aim of this project is to come up with new strategies to fight multidrug resistance, unresolved infections and rare diseases focusing in the areas of advanced therapies (CAR-T & BiTes), new bacteriophage-based treatments, antisense oligonucleotides and monoclonal immunotherapies. The grant, which represents more than 50% of the submitted project’s value, underscores the strong alignment between REIG JOFRE’s proposal and the strategic objectives of the European Med4Cure program. Beyond its scientific scope, EMINTECH aims to activate a collaborative innovation ecosystem, in synergy with other European partners of the Med4Cure project, to accelerate technology transfer from the laboratory to clinical practice and enable its industrial scaling. Backed by this investment, the project will foster the creation of highly qualified jobs, strengthen public-private collaboration, and contribute to the development of a more sustainable pharmaceutical production model, aligned with the Sustainable Development Goals (SDGs) |
| Duration: | 2023-2026 |
| Project title: | BRIDGE: Biomanufacturing Regions for Integrated Development and Growth in the Ecosystems |
|---|---|
| Logo: |  |
| Reference Number: | 101225477 |
| Partners: | DISTRETTO TECNOLOGICO CAMPANIA BIOSCIENCE SCARL (CBIOS) CENTRO REGIONALE DI COMPETENZA IN BIOTECNOLOGIE INDUSTRIALI BIOTEKNET SOCIETA CONSORTILE PER AZIONI (BioTekNet) BIOCAT LA FUNDACIO BIOREGIO DE CATALUNYA (BIOCAT) FUNDACION EIT HEALTH SPAIN (EIT Health) LABORATORIO REIG JOFRE SA (RJF) POLITECHNIKA SLASKA (SUT) GORNOSLASKI AKCELERATOR PRZEDSIEBIORCZOSCI RYNKOWEJ SP Z O.O. (GAPR) EIT HEALTH INNOSTARS EV (INN) |
| Funding Agency: | This project has received funding from the European Union’s Capacity Building Strand 2b (I3-2023-CAP2b) call
|
| Objetive: | BRIDGE connects Catalonia (ES) and two other European regions, Silesia (PL) and Campania (IT) in the field of biomanufacturing, creating an interconnected ecosystem of biomanufacturing nodes and forges their cooperation via knowledge-transfer activities, industry-driven joint value-chain initiatives, funding mapping and via access to the most advanced innovation support and exchange mechanisms and network provided by EIT Health InnoStars. The project will lead to identifying a pipeline of interregional investment opportunities in alignment with S3 priorities that will be promoted via enhanced innovation support measures and channelled towards regional, national and EU funding opportunities. |
| Duration: | 2025-2027 |
| Project title: | BREATH: Empowering Research Talent: Building R&I Talent Ecosystems to Advance Careers in Health Innovation |
|---|---|
| Logo: |  |
| Reference Number: | 101217137 |
| Partners: | 1 UNIVERSITAT AUTONOMA DE BARCELONA ES 2 BIOCAT LA FUNDACIO BIOREGIO DE CATALUNYA ES 3 AGENCIA DE GESTIO D’AJUTS UNIVERSITARIS I DE RECERC ES 4 GENERALITAT DE CATALUNYA DEPARTAMENT DE RECERC ES 5 WEDO PROJECT INTELLIGENCE MADE EASYSL ES 6 KATHOLIEKE UNIVERSITEIT LEUVEN BE 7 MEDVIA BE 8 COUNCIL OF EUROPEAN BIOREGIONS BE 9 KAUNO TECHNOLOGIJOS UNIVERSITETAS LT 10 VIESOJI ISTAIGA INOVACIJU AGENTURA LT 11 LIETUVOS RESPUBLIKOS SVIETIMO, MOKSLO IR SPORTO M LT 12 FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES 13 LABORATORIO REIG JOFRE SA ES 14 UAB CURELINE BALTIC LT 15 UAB “”Nando”” LT 16 ALIRA HEALTH SL Spain |
| Funding Agency: | This project has received funding from the European Union’s HORIZON-WIDERA-2024-ERA-02 call
|
| Objetive: | BREATH aims to address the lack of diverse and sustainable career development opportunities for researchers in Europe, which impacts talent retention and innovation capacity. The BREATH project aims to enhance Health Innovation (HI) research talent management in Catalonia, Flanders, and Lithuania. It seeks to improve services for researchers, foster attractive career opportunities, and promote international collaboration. The project involves academic and non-academic institutions working together to set priorities and test governance models that encourage collaboration between academia and research employers |
| Duration: | 2025-2028 |
| Project title: | ERDERA: the European Rare Diseases Research Alliance |
|---|---|
| Logo: |  |
| Reference Number: | 101156595 |
| Partners: | European partnership uniting over 170 public and private organisations across 37 countries |
| Funding Agency: | This project has received funding from the European Union’s Horizon Europe research and innovation programme
|
| Objetive: | The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the people living with a rare disease in Europe, by making Europe a world leader in Rare Disease (RD) research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment. This Partnership will deliver a RD ecosystem that builds on the successes of previous programmes by supporting robust patient need-led research, developing new diagnostic methods and pathways, spearheading the digital transformational change connecting the dots between care, patient data and research, while ensuring strong alignment of strategies in RD research across countries and regions. |
| Duration: | 2024-2031 |
| Project title: | POLYCYSTIC OVARY SYNDROME (PCOS) IN ADOLESCENT GIRLS AND YOUNG WOMEN: TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY. (SPIOMET4HEALTH) |
|---|---|
| Logo: |  |
| Reference Number: | 899671 |
| Partners: | FUNDACIÓ SANT JOAN DE DÉU/HOSPITAL SANT JOAN DE DÉU UNIVERSIDAD KU LEUVEN FUNDACIÓ INSTITUT D’INVESTIGACIÓ BIOMÈDICA DE GIRONA DOCTOR JOSEP TRUETA UNIVERSIDAD WITTEN/HERDECKE UNIVERSIDAD MÉDICA DE GRAZ, REGION SYDDANMARK UNIVERSIDAD NORUEGA DE CIENCIA Y TECNOLOGÍA UNIVERSIDAD ALMA MATER STUDIORUM DE BOLONIA UNIVERSIDAD DE ISTANBUL OPTIMAPHARM LABORATORIO REIG JOFRE SA UNIVERSIDAD COMPLUTENSE DE MADRID OUTCOMES’10 SL INSTITUTO EUROPEO DE LA SALUD DE LA MUJER DELEGACIÓN DE LA UE «MAKE MOTHERS MATTER» ASPHALION SL ZABALA INNOVATION. |
| Funding Agency: | This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899671 |
| Objetive: | The main objective of SPIOMET4HEALTH is to test, in a multi-centre Phase II clinical trial, a novel treatment for adolescent girls and young adult women with PCOS. |
| Duration: | 2021-2026 |
| Web: | spiomet4health.eu |
| Project title: | Boosting the reduction of the Envitonmental impact of pharmaceutical products throughout their entire life cycle. (ETERNAL) |
|---|---|
| Logo: |  |
| Reference Number: | 101057668 |
| Partners: | AIMPLAS – ASOCIACION DE INVESTIGACION DE MATERIALES PLASTICOS Y CONEXAS IRIS TECHNOLOGY SOLUTIONS MYBIOTECH GMBH ENVIROEYE ENGINEEING LTD UNIVERSITAET FUER BODENKULTUR WIEN (BOKU) AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO (ANGELINI PHARMA) UNIVERSIDADE DE AVEIRO (UAVR) LABORATORIO REIG JOFRE SA ASPHALION SL ASOCIACION ESPANOLA DE NORMALIZACION (UNE) INLECOM COMMERCIAL PATHWAYS COMPANY LIMITED BY GUARANTEE UNIVERSITAT DES SAARLANDES (USAAR) BRITEST LIMITED UK CENTRE FOR ECOLOGY & HYDROLOGY (UKCEH) QUOTIENT SCIENCES (ALNWICK) LIMITED ASTRAZENECA UK LIMITED |
| Funding Agency: | This project has received funding from the European Union’s Horizon 2020 research and innovation program. |
| Objetive: | ETERNAL’s overall purpose is to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, use, and disposal. This includes assessing the environmental risks of active pharmaceutical ingredients, residues, metabolites, and other chemicals and by-products of the production process. This project is essential for developing environmentally friendly industrial processes. In particular, Reig Jofre applies it to the sustainable development of new drugs based on lipid nanoparticles. |
| Duration: | 2022-2026 |
| Web: | eternalproject.eu |